MilliporeSigma
Search Within
Applied Filters:
Keyword:'33999'
Showing 1-30 of 51 results for "

33999

" within Papers
A Tursi et al.
European review for medical and pharmacological sciences, 17(3), 342-348 (2013-02-22)
Colonic diverticulitis shows a high recurrence rate. To assess the efficacy of three different therapeutic strategies in preventing diverticulitis recurrence. One hundred thirty patients suffering from Acute Uncomplicated Diverticulitis (AUD) (81 males, 49 females, mean age 64.71 years, range 40-85)
Roxana Irimia et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 116(4), 1021-1027 (2013-05-25)
Both rifaximin and lactulose have been reported to be effective for maintenance of remission from hepatic encephalopathy (HE) in patients with cirrhosis. The aim of this study was to compare the efficacy of different treatment strategies for preventing recurrences and
Jiannis Vlachogiannakos et al.
Journal of gastroenterology and hepatology, 28(3), 450-455 (2012-12-12)
Cirrhotic patients are predisposed to intestinal bacterial overgrowth with translocation of bacterial products which may deteriorate liver hemodynamics. Having shown that short-term administration of rifaximin improves liver hemodynamics in decompensated cirrhosis, we conducted this study to investigate the effect of
S S Belous et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (3)(3), 63-68 (2013-12-04)
One of the important problems in the treatment of patients with inflammatory bowel disease are the persistent complaints of pain, abdominal distention, frequent stools, excretion of mucus with faeces with the presence of endoscopic or roentgenologic remission in the damaged
Anastasia Rivkin et al.
Clinical therapeutics, 33(7), 812-827 (2011-07-12)
Rifaximin is a nonabsorbable oral antibiotic that acts locally in the gastrointestinal tract with minimal systemic adverse effects. Rifaximin received new labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver
Yangmin Hu et al.
Journal of travel medicine, 19(6), 352-356 (2013-02-06)
Rifaximin has been used successfully for the prevention of travelers' diarrhea (TD), the most general cause of disability among international travelers to developing tropical and semitropical regions. We sought to better evaluate the efficacy of rifaximin in the prevention of
Rifaximin plus fibre versus fibre alone in preventing diverticulitis recurrence: a (problematic) trial to tackle an epidemiologically relevant problem.
Dario Conte et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 45(2), 102-103 (2013-01-10)
Rima I El-Herte et al.
Scandinavian journal of infectious diseases, 44(3), 228-230 (2011-11-15)
Clostridium difficile colitis infection is on the rise and is considerably increasing the duration of hospital stay, as well as healthcare costs. The management of C. difficile colitis has become more challenging with the increasing failure of therapeutic response to
Rima A Mohammad et al.
The Annals of pharmacotherapy, 46(11), 1559-1563 (2012-10-25)
To evaluate the efficacy and safety of combination therapy for the treatment and prevention of hepatic encephalopathy (HE). A PubMed MEDLINE search was conducted (1947-June 2012) using the key terms lactulose, lactitol, nonabsorbable disaccharide, metronidazole, rifaximin, neomycin, probiotics, and hepatic
David J Farrell
Journal of clinical gastroenterology, 47(3), 205-211 (2013-01-24)
Irritable bowel syndrome (IBS), a chronic, nonfatal illness is commonly encountered in clinical practice; however, treatment options are limited and often ineffectual. Despite this, there is increasing evidence that bacterial overgrowth in the bowel (dysbiosis) may be an etiological factor
Sean Bandzar et al.
Cellular immunology, 286(1-2), 45-52 (2013-12-11)
Crohn's disease is an autoimmune disorder that affects nearly 1.4 million Americans. The etiology of Crohn's disease is not completely understood, however, research has suggested a genetic link. There is currently no known cure for Crohn's disease and, as a
Pramodini B Kale-Pradhan et al.
Expert review of gastroenterology & hepatology, 7(3), 281-288 (2013-03-01)
This review summarizes literature regarding the role of antimicrobials for induction and maintenance of Crohn's disease (CD) remission. PubMed was searched (1966 to October 2012) for controlled trials involving adults and written in English. Five of the 13 identified studies
Adriana Stoicescu et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 116(3), 766-772 (2013-01-01)
Some patients previously diagnosed with irritable bowel syndrome (IBS) may develop microscopic colitis or small intestinal bacterial overgrowth (SIBO). To estimate the prevalence of microscopic colitis and SIBO in patients with IBS, to evaluate the symptoms and the efficacy of
Prevention of travellers' diarrhoea: where and who?
Joaquim Ruiz et al.
The Lancet. Infectious diseases, 13(11), 911-912 (2013-09-10)
Angel Lanas et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 45(2), 104-109 (2012-10-25)
Evidence supporting appropriate medical therapy to prevent recurrence of colonic diverticulitis is limited. Our goal was to evaluate the potential of rifaximin given periodically in addition to fibre for the prophylaxis of recurrences. We conducted a multicentre, randomized, open controlled
T Rabenstein et al.
Zeitschrift fur Gastroenterologie, 49(2), 211-224 (2011-01-13)
Rifaximin, a non-resorbable broadband antibiotic, was approved in Germany 2 years ago for the treatment of traveller's diarrhoea caused by non-invasive enteropathogens. On account of the very good tolerance and the high efficacy against almost all enteropathogens this pharmaceutical, which
Veronica Ojetti et al.
Expert opinion on drug metabolism & toxicology, 5(6), 675-682 (2009-05-16)
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, with a low gastrointestinal absorption and a good antibacterial activity. The antibacterial action covers Gram-positive and Gram-negative organisms, both aerobes and anaerobes. Its antimicrobial action is based on its property to bind to
Karim M Eltawil et al.
World journal of gastroenterology, 18(8), 767-777 (2012-03-01)
To characterize the efficacy of rifaximin in the management of hepatic encephalopathy (HE) as several randomized controlled studies have shown contradictory results on its effectiveness in comparison to other oral agents. We performed a systematic review and random effects meta-analysis
Infection prevention considerations related to New Delhi metallo-β-lactamase Enterobacteriaceae: a case report.
Ramya Gopinath et al.
Infection control and hospital epidemiology, 34(1), 99-100 (2012-12-12)
[Irritable bowel disease: recent developments].
S K Böhm et al.
Deutsche medizinische Wochenschrift (1946), 137(40), 2034-2037 (2012-10-02)
Lise Lotte Gluud et al.
Metabolic brain disease, 28(2), 221-225 (2013-01-01)
Hepatic encephalopathy (HE) is a serious complication of acute and chronic liver disease associated with severe morbidity and mortality. We performed updated random effects meta-analyses to evaluate the evidence for non-absorbable disaccharides (lactulose and lactitol), rifaximin and branched chain amino
Jie Cheng et al.
The Journal of pharmacology and experimental therapeutics, 351(3), 559-567 (2014-10-04)
The role of intestinal human pregnane X receptor (PXR) in colon cancer was determined through investigation of the chemopreventive role of rifaximin, a specific agonist of intestinal human PXR, toward azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon cancer. Rifaximin treatment significantly
E Scarpellini et al.
European review for medical and pharmacological sciences, 17(10), 1314-1320 (2013-06-07)
Aims of the study were to assess the effects of rifaximin treatment on small intestinal bacterial overgrowth (SIBO) prevalence and gastrointestinal symptoms. Fifty (50) irritable bowel syndrome (IBS) children were consecutively enrolled. All subjects underwent lactulose hydrogen/methane breath test (LBT)
Eszter Tuboly et al.
American journal of physiology. Cell physiology, 304(2), C207-C214 (2012-11-24)
Previous studies demonstrated methane generation in aerobic cells. Our aims were to investigate the methanogenic features of sodium azide (NaN(3))-induced chemical hypoxia in the whole animal and to study the effects of l-α-glycerylphosphorylcholine (GPC) on endogenous methane production and inflammatory
Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
Beverley Kok et al.
Hepatology (Baltimore, Md.), 58(4), 1516-1517 (2013-03-09)
E Mattila et al.
Alimentary pharmacology & therapeutics, 37(1), 122-128 (2012-10-26)
Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that has effect against
Kenneth R Lawrence et al.
Pharmacotherapy, 28(8), 1019-1032 (2008-07-29)
To review the effectiveness and safety of rifaximin for the treatment of hepatic encephalopathy. A literature search was conducted of MEDLINE (1966-September 2007), the Cochrane Database of Systematic Reviews (1995-2007), and the Cochrane Hepato-Biliary Group Reviews (2003-2007). English-language articles identified
Vishesh Kothary et al.
Antimicrobial agents and chemotherapy, 57(2), 811-817 (2012-11-28)
Escherichia coli is implicated in the pathogenesis of inflammatory bowel disease (IBD). Rifaximin, a nonabsorbable derivative of rifampin effective against E. coli, improves symptoms in mild-to-moderate IBD. However, rifaximin resistance can develop in a single step in vitro. We examined
Rifaximin may have a dramatic effect on hepatic encephalopathy.
Christopher Lamb et al.
Clinical medicine (London, England), 12(5), 489-490 (2012-10-30)
Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin.
Leonard B Weinstock et al.
Journal of the American Academy of Dermatology, 68(5), 875-876 (2013-04-23)
Page 1 of 2
Page 1 of 2